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2Abstract
OBJECTIVE To investigate how risk of end-stage renal disease among patients with type 1
diabetes has changed over time, and further how the risk is affected by age, sex, and time
period of diagnosis of diabetes.
RESEARCH DESIGN AND METHODS A cohort including all patients younger than 30
years diagnosed with type 1 diabetes in Finland in 1965–2011 was followed until start of
renal replacement therapy, death, or end of follow-up at the end of 2013. Altogether 29 906
patients were included. The main outcome was cumulative risk of end-stage renal disease,
accounting for death as a competing risk.
RESULTS The patients were followed up for a median of 20 years. During 616 403 patient-
years, 1 543 end-stage renal disease cases and 4 185 deaths were recorded. The cumulative
risk of end-stage renal disease was 2.2% after 20 years, and 7.0% after 30 years from the
diabetes diagnosis. The relative risk of end-stage renal disease was 0.13 [95%CI 0.08–0.22)
among patients diagnosed in 1995–2011 compared to those diagnosed in 1965–1979. Patients
younger than 5 years at the time of diagnosis had the lowest risk of end-stage renal disease
after diagnosis. If the cumulative risk of end-stage renal disease was estimated from time of
birth, the patients aged 5–9 years at diabetes diagnosis were at highest risk.
CONCLUSIONS The cumulative risk of end-stage renal disease has decreased markedly
during the past five decades. This highlights the importance of modern treatment of diabetes
and diabetic nephropathy.
3Introduction
It is well known that diabetic nephropathy is associated with increased morbidity and
mortality in patients with type 1 diabetes, and end-stage renal disease (ESRD) increases the
mortality markedly (1-4). However, the risk of diabetic nephropathy has decreased during the
past decades probably because of improvements in glucose and blood pressure control (5-7).
In 2005 we showed that the risk of ESRD among patients with type 1 diabetes had diminished
during the past 4 decades and was only 7.8% at 30 years after the diabetes diagnosi (8). A
more recent study on Swedish patients with type 1 diabetes reported an even lower
cumulative incidence of ESRD (9).
Many studies have reported better renal prognosis if type 1 diabetes is diagnosed before
puberty (8-10), but the results on the effect of sex have been conflicting (8,9,11,12). The
incidence of ESRD starts to increase after 15 years and continues to increase up to 30 years
from the diabetes diagnosis, and it has been suggested that new treatments have postponed the
development of ESRD (8,13). The use of multiple injection insulin therapy, angiotensin
converting enzyme inhibitors, angiotensin 2 receptor blockers, and statins has become
increasingly common from the 1990’s, and therefore only now we are able to see a possible
effect of long-term use of these medications on the risk of ESRD.
It is of note that compared to previous reports our study population is comprehensive with an
almost 50 year study period and complete coverage of patients with type 1 diabetes in
Finland. The aim of this nationwide population-based study was to investigate how the trends
in risk of ESRD have changed in patients with type 1 diabetes during last 5 decades.
4Research Design and Methods
Study population
Patients with type 1 diabetes were identified from the FinDM II study (14), which has
collected information on patients with diabetes in Finland. A primary source of this
information is the register of entitlements to special reimbursement for medicines maintained
by the Finnish Social Insurance Institution. In Finland insulin therapy has been fully
reimbursed since 1964 for patients diagnosed with type 1 diabetes, and therefore the coverage
of patients with type 1 diabetes in the register is complete. We selected all patients with type 1
diabetes, who had started insulin therapy before the age of 30 years between 1965 and 2011.
For this population, we also obtained data on purchases of other medications from the Finnish
Social Insurance Institution prescription database for the period between 1993 and 2011.
Thus, patients using metformin (n=264) or other oral medication (n=49) used for type 2
diabetes within one year from the start of insulin therapy were excluded from the study. In
addition, those patients having a diagnosis of secondary diabetes (n=221) in the Finnish Care
Register were excluded. After these exclusions a total of 29 906 patients with type 1 diabetes
were included in the study. ESRD was defined as onset of renal replacement therapy (RRT)
based on information from the Finnish Registry for Kidney Diseases, which has almost full
coverage (97-99%) of patients starting RRT (dialysis or kidney transplantation) in Finland
since 1965 until the end of 2013. Information on deaths from 1965 until the end of 2013 was
obtained from the Cause of Death Register maintained by Statistics Finland. Linkage between
different registries was possible because of the Finnish system of unique personal
identification numbers for all citizens. Notably, all data in this study were obtained from
registries fully financed by the Finnish government. The ethics committee of the Finnish
National Institute for Health and Welfare has approved the use of patient data for the FinDM
II study, and the patients in the Finnish Registry for Kidney Diseases provided written
5informed consent for use of their data for research purposes, and therefore separate approval
by an ethics committee was not needed for this observational study.
Statistical methods
Patients were followed from the start of insulin therapy marking the onset of diabetes until the
start of RRT, death, or end of follow up on 31 December 2013. Death is a competing risk
event for ESRD as deceased patients are no longer at risk of ESRD. Therefore, the cumulative
risk of ESRD was calculated using a method that takes into account the effect of death as a
competing risk event. All-cause mortality was assessed using Kaplan-Meier survival
probabilities. Cox proportional hazards- model was used to assess the relative risks of ESRD
and death. Effect of age at diagnosis, time period of diagnosis, sex and the time-dependent
variable of ESRD were estimated using Cox regression model.
The R statistical software 3.2.2 (The R Foundation for Statistical Computing, Vienna, Austria;
available at http://www.r-project.org) and SAS statistical software, release 9.3 (SAS Institute
Inc., Cary, NC, USA) were used to perform the statistical analyses.
Results
Altogether 29 906 patients aged under 30 years were diagnosed with type 1 diabetes in
Finland in 1965-2011, of which 17 365 were men (58%). Median age at diabetes diagnosis
was 12.5 years, and median follow-up time after diagnosis of diabetes was 20.3 years (Table
1). During 616 403 patient-years of follow-up, 1 543 ESRD cases and 4 185 deaths were
recorded.
6The incidence rate of ESRD started to rise 15 years after the diabetes diagnosis, increased up
to 25 years from diagnosis, and thereafter reached a plateau and remained at the same level
until the end of the 45-year follow-up in patients diagnosed 1965-69. However, the incidence
rate at 16-20 years from the diabetes diagnosis has become lower over time (Figure 1). The
cumulative incidence of ESRD was 2.2% (95% CI 2.0 to 2.4%) after 20 years, and 7.0%
(95% CI 6.6 to 7.4%) after 30 years among all patients in the study cohort. However, if
including only those diagnosed with diabetes after 1980, the cumulative incidence was only
1.3% (95% CI 1.1 to 1.5%) and 4.4% (95% CI 3.8 to 5.0%), respectively. Figure 2 shows the
cumulative incidence of ESRD according to sex and age at diabetes diagnosis. The
cumulative incidence of ESRD after 30 years was higher among men 7.7% (95% CI 7.1 to
8.3%) than women 6.0% (95% CI 5.4 to 6.6%). Patients diagnosed with type 1 diabetes
before the age of five years had the lowest cumulative incidence of ESRD, but otherwise there
was no association with age at diagnosis and risk of ESRD. The results were similar if
including only the patients diagnosed with diabetes after 1980. The cumulative incidence was
the second lowest in the age-group 5-9-years until approximately 25 years of follow-up, after
which the incidence started to catch up and even overtake the cumulative incidence in the age
groups 10-29 years.
Although the cumulative risk of ESRD, as assessed from time of diagnosis of diabetes, was
the lowest among patients diagnosed under the age of five, the cumulative risk of ESRD as
assessed from time of birth was 12.1% in men and 13.2% in women at age 50, compared
to 3.5% and 2.1%, respectively, among those diagnosed with diabetes at age 25-29 years
(Figure 2).
In multivariable analysis (Table 2), the patients diagnosed with type 1 diabetes before the age
of 5 years had significantly lower risk of ESRD, whereas there was no difference in the risk
between the older age group. The risk of ESRD was 26% lower among women than men. A
7diabetes diagnosis in 1965-79 was associated with the highest risk of ESRD, but the prognosis
has improved continuously during later time periods.
Only a small portion of the deceased patients had ESRD. The cumulative all-cause-mortality
was 7.0% (95% CI 6.7 to 7.4%) at 20 years and 12.5% (95% CI 12.0 to 13.0%) at 30 years
after the diabetes diagnosis. Hereby, the cumulative mortality was markedly higher than the
cumulative incidence of ESRD. This highlights the importance of death as a competing risk
event that reduces the risk of ever developing ESRD. Consequently, the adjusted relative risk
of death in patients with type 1 diabetes and ESRD was 10.2 (95% CI 9.4 to 11.1) compared
to other patients with type 1 diabetes, showing the considerable impact of ESRD on mortality
in these patients. The relative risk of death was 34% lower in women than men. The risk of
death increased with older age at diabetes diagnosis, while a later time period of diagnosis
was associated with lower risk of death (Table 2).
Conclusions
We here showed that the risk of ESRD has decreased continuously over time and that the
progression of diabetic nephropathy and renal failure is slower than before among patients
with type 1 diabetes. However, type 1 diabetes is still a notable cause of ESRD, and
comprised 14% of all patients who entered RRT in Finland in 2011-2015 (15). Within 30
years from the diagnosis of type 1 diabetes 7.0% of the patients developed ESRD, and the risk
of death among these patients was 10 times as high as in other patients with type 1 diabetes.
Although ESRD developed more slowly, the life-time risk of ESRD was the highest if
diabetes was diagnosed at younger age. This nationwide study covering almost 50 years and
29 906 patients is the largest one to study the incidence in patients with type 1 diabetes.
8We were able to perform this study, because of the national registries in Finland, which cover
practically all patients with type 1 diabetes, all patients with ESRD, and all deaths during the
past decades. Unique personal identification numbers for all citizens enabled linkage between
these registries. For this reason, we could avoid selection bias, and assess how the incidence
of ESRD has changed by time. It is of note that the incidence of type 1 diabetes in Finland is
the highest in the world (16), and a lot of efforts and resources have consequently been
invested in the treatment and study of these patients. It is therefore possible that this could
have led to better prognosis of the patients with type 1 diabetes in Finland compared to many
other countries (17). In addition, the Finnish population is almost entirely Caucasian and
genetically homogenous. For these reasons, our results may not be directly generalizable to
other parts of the world. In regression analyses it has to be taken into account that Kaplan-
Meier curves according to age groups do not fulfil the proportional hazards assumption.
Shapes of the curves are different if diabetes is diagnosed before or after ten-years of age,
probably because of the influence of puberty.
In 2005 we showed that the cumulative incidence of ESRD in patients with type 1 diabetes
was 7.8% after 30 years (8), which was lower than previously reported (18). Later a large
population-based study from Sweden (n=11 681) reported an even lower cumulative
incidence of ESRD, 3.3% after 30 years (9). The patient selection and study design was
similar to ours, but the study period started later and hereby the follow-up period was shorter.
In contrast a study from Pittsburgh, United States, showed a markedly higher incidence rate of
ESRD for patients diagnosed 1965-1980. The cumulative incidence after 30 years was 13.7%
for men, and 21.0% for women, but the incidence was even higher if diabetes was diagnosed
1950-1964, namely 43.4% for men and 24.6% for women, respectively (12). At least part of
these differences can be explained by an earlier study period and a different patient selection.
Another study from United States reported a decline in the cumulative incidence rates of
9ESRD. If type 1 diabetes was diagnosed between 1975 and 1979, the 20-year cumulative
incidence was 3.6% (19). Notably studies from Europe, Canada, and Australia have also
reported declining incidence rates as well as an increase in the age at start of RRT in patients
with type 1 diabetes (7,15,20,21), which is in line with our results. However, the incidence of
ESRD caused by type 1 diabetes in the United States has not decreased but rather increased
over the past 20 years, although also there it nowadays occurs at slightly older ages (22).
Importantly, there was no risk reduction of ESRD despite of efficient renoprotective
medication (23). Furthermore, it must be kept in mind that the prognosis of patients with type
1 diabetes and diabetic nephropathy is still poor in the developing countries (24).
There is strong evidence that better glucose control as well as treatment of hypertension and
dyslipidemia decrease the risk of diabetic nephropathy and ESRD in patients with type 1
diabetes (7,25-31). The use of multiple insulin injections became more common in the 1990s,
and was followed by the development of rapid-acting and long-acting insulin regimens, which
enabled patients with type 1 diabetes to maintain a more stable blood glucose control. Also
the use and variety of medication for dyslipidemia and hypertension has increased from
1990s. For instance angiotensin converting enzyme inhibitors and angiotensin receptor
blockers have become a mainstay in the treatment of diabetic nephropathy during recent
decades. As our study showed, the incidence of ESRD after 30 years has decreased over time.
However, because there has been a broad use of these medications for only less than 20 years,
we could expect to see a further decrease in the incidence of ESRD in the future. Although the
risk of ESRD cannot be fully eliminated, the development of this devastating complication
can probably be moved forward (32). Postponing kidney failure and the start of RRT start will
increase quality of life, and reduce medical expenses.
Previous reports have showed conflicting results on how sex affects the incidence of ESRD
among patients with type 1 diabetes. Many studies have reported that men more frequently
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develop diabetic nephropathy (2,30,33), but the incidence of ESRD seems more complex.
Costacou et al showed that the incidence of ESRD was higher among men if diabetes was
diagnosed in 1950-1964, but if diabetes was diagnosed 1965-1980, the male excess was
eliminated (12). There is evidence that the risk of ESRD is equal in men and women if
diabetes is diagnosed during childhood, but if diabetes develops after puberty, the risk of
ESRD is higher among men (9,11). This suggests a role of sex hormones. Supporting this
theory, we showed in this study that the risk of ESRD is higher among men only if diabetes is
diagnosed after puberty.
Diabetic nephropathy, especially when it proceeds to ESRD, is associated with an increased
risk of premature death (1,2,33). Patients with type 1 diabetes and ESRD are estimated to
have 18- to 30-fold higher standardized mortality ratio compared to the general population
(3,4). Our study also showed a 10 fold-risk among type 1 diabetes patients with compared
those without ESRD. However, the survival of patients with type 1 diabetes on RRT has
improved during recent decades (34).
In conclusion, the risk of ESRD in patients with type 1 diabetes has decreased over time.
Females and those diagnosed with type 1 diabetes at younger age are at lower risk, although
the lifetime risk of ESRD is the highest among patients diagnosed with diabetes before the
age of 10 years. Because modern treatment of diabetes with multiple insulin injections, renin-
angiotensin system inhibitors, and statin therapy has been mainstay only for less than 20
years, there is hope that the cumulative incidence of ESRD will continue to decrease in the
future.
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Figure 1. Incidence of Renal Replacement Therapy after Diagnosis of Type 1 Diabetes
12
Figure 2. Cumulative Incidence of End-Stage Renal Disease after Type 1 Diabetes Diagnosis
and from Birth among Male and Female According to Age at Diagnosis of Diabetes
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Table 1. Number of Males and Females Diagnosed as Having Type 1 Diabetes in Finland
According to Age and Time Period of Diagnosis
Age
group
Sex 1965-79 1980-1984 1985-89 1990-94 1995-2011 Total
0-4 years Total 808 328 378 501 2371 4386
Males 431 184 208 254 1273 2350
Females 377 144 170 247 1098 2036
5-9 years Total 1577 590 638 693 3216 6714
Males 813 313 354 351 1676 3507
Females 764 277 284 342 1540 3207
10-14
years
Total 2147 663 630 684 3059 7183
Males 1155 375 368 374 1799 4071
Females 992 288 262 310 1260 3112
15-19
years
Total 1619 420 374 385 1479 4277
Males 984 259 232 247 991 2713
Females 635 161 142 138 488 1564
20-24
years
Total 1414 388 377 328 1040 3547
Males 839 228 220 194 692 2173
Females 575 160 157 134 348 1374
25-29
years
Total 1466 401 448 380 1104 3799
Males 960 276 302 245 768 2551
Females 506 125 146 135 336 1248
0-29
years
Total 9031 2790 2845 2971 12269 29906
Males 5182 1635 1684 1665 7199 17365
Females 3849 1155 1161 1306 5070 12541
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Table 2. Relative Risks of ESRD and Death Associated with Sex, Age, and Time Period of
Diagnosis of Type 1 Diabetes
Variable ESRD
RR 95% CI P Value
Death
RR 95% CI P Value
Sex Male 1 1
Female 0.74 0.67-0.82 <.001 0.66 0.62-0.71 <.001
Age
(Years)
0-4 1 1
5-9 1.83 1.45-2.31 <.001 1.58 1.32-1.89 <.001
10-14 2.00 1.60-2.51 <.001 2.01 1.70-2.38 <.001
15-19 1.90 1.50-2.40 <.001 2.85 2.41-3.38 <.001
20-24 2.02 1.59-2.58 <.001 4.57 3.87-5.39 <.001
25-29 2.16 1.69-2.75 <.001 6.52 5.54-7.67 <.001
Year of
Diabetes
Diagnosis
1965-79 1 1
1980-84 0.56 0.48-0.67 <.001 0.64 0.57-0.71 <.001
1985-89 0.40 0.32-0.50 <.001 0.48 0.42-0.55 <.001
1990-94 0.32 0.23-0.44 <.001 0.47 0.40-0.55 <.001
1995-2011 0.13 0.08-0.22 <.001 0.27 0.23-0.32 <.001
Abbreviations: ESRD, end-stage renal disease; RR, relative risk; CI, confidence interval
